-
公开(公告)号：US20180186897A1
公开(公告)日：2018-07-05
申请号：US15738828
申请日：2016-06-24
发明人： Antonio Lanzavecchia , Roger Geiger , Luca Piccoli
IPC分类号： C07K16/44 , A61P33/06 , C07K14/705 , G01N33/569
CPC分类号： C07K16/44 , A61K39/015 , A61P33/06 , C07K14/70503 , C07K14/70596 , C07K16/28 , C07K2317/21 , C07K2317/30 , C07K2319/33 , G01N33/569 , G01N33/56905 , G01N2333/445 , G01N2800/26 , Y02A50/412 , Y02A50/58
摘要： The present invention provides a pharmaceutical composition, for example a vaccine, which comprises a RIFIN, which is able to bind to a mutated LAIR-1 fragment, which broadly binds to erythrocytes infected with Plasmodium falciparum. Such a RIFIN may be useful in the prevention and/or treatment of malaria.
-
公开(公告)号：US10526404B2
公开(公告)日：2020-01-07
申请号：US15568325
申请日：2015-04-29
发明人： Davide Corti , Antonio Lanzavecchia , Luca Piccoli
摘要： The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non-overlapping sites in a cytokine and an Fc moiety. The invention also relates to nucleic acids that encode such antibodies and antibody fragments and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of inflammatory and/or autoimmune diseases.
-
公开(公告)号：US20180179274A1
公开(公告)日：2018-06-28
申请号：US15738912
申请日：2016-06-24
发明人： Antonio Lanzavecchia , Joshua Tan , Abdi Abdirahman , Kathrin Pieper , Luca Piccoli , Peter Charles Bull
IPC分类号： C07K16/20 , A61P33/02 , G01N33/569 , C07K14/705
CPC分类号： C07K16/205 , A61K38/00 , A61K2039/505 , A61P33/02 , C07K14/70503 , C07K16/2803 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2319/30 , G01N33/56905 , G01N2333/445 , G01N2800/26 , Y02A50/412 , Y02A50/58
摘要： The present invention provides a protein comprising a mutated LAIR-1 fragment, which broadly binds to erythrocytes infected with Plasmodium falciparum. The protein comprising the mutated LAIR-1 fragment may be useful in the prevention and/or treatment of malaria. The present invention furthermore provides a nucleic acid encoding a mutated LAIR-1 fragment, a vector comprising such a nucleic acid as well as a respective pharmaceutical composition.
-
公开(公告)号：US11261245B2
公开(公告)日：2022-03-01
申请号：US16691338
申请日：2019-11-21
发明人： Davide Corti , Antonio Lanzavecchia , Luca Piccoli
摘要： The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non-overlapping sites in a cytokine and an Fc moiety. The invention also relates to nucleic acids that encode such antibodies and antibody fragments and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of inflammatory and/or autoimmune diseases.
-
-
-
搜索结果
4 条记录 (耗时 0.02 秒)
